Clinical application of serum anti-Müllerian hormone in women
10.5653/cerm.2019.46.2.50
- Author:
So Ra OH
1
;
Sun Yi CHOE
;
Yeon Jean CHO
Author Information
1. Department of Obstetrics and Gynecology, Dong-A University Medical Center, Dong-A University College of Medicine, Busan, Korea. jeanjane@dau.ac.kr
- Publication Type:Review
- Keywords:
Anti-Müllerian hormone;
Fertility;
Ovarian reserve;
Polycystic ovary syndrome;
Surgery
- MeSH:
Drug Therapy;
Female;
Fertility;
Fertilization;
Gynecologic Surgical Procedures;
Humans;
Menopause;
Ovarian Reserve;
Polycystic Ovary Syndrome;
Reproductive Techniques, Assisted
- From:Clinical and Experimental Reproductive Medicine
2019;46(2):50-59
- CountryRepublic of Korea
- Language:English
-
Abstract:
Anti-Müllerian hormone (AMH), a peptide growth factor of the transforming growth factor-β family, is a reliable marker of ovarian reserve. Regarding assisted reproductive technology, AMH has been efficiently used as a marker to predict ovarian response to stimulation. The clinical use of AMH has recently been extended and emphasized. The uses of AMH as a predictive marker of menopause onset, diagnostic tool for polycystic ovary syndrome, and assessment of ovarian function before and after gynecologic surgeries or gonadotoxic agents such as chemotherapy have been investigated. Serum AMH levels can also be affected by environmental and genetic factors; thus, the effects of factors that may alter AMH test results should be considered. This review summarizes the findings of recent studies focusing on the clinical application of AMH and factors that influence the AMH level and opinions on the use of the AMH level to assess the probability of conception before reproductive life planning as a “fertility test.”
